Optimising High-Potency Manufacture

Article

Pharmaceutical Technology Europe

Pharmaceutical Technology EuropePharmaceutical Technology Europe-06-01-2011
Volume 23
Issue 6

Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.

High-containment manufacturing, whether for an active pharmaceutical ingredient or finished drug product, requires specialized approaches in facility design, equipment selection, and manufacturing processes to achieve the desired levels of containment and minimize operator exposure. As with pharmaceutical manufacturing overall, science- and risk-based approaches to reach those goals serve as a crucial framework for optimizing high-potency manufacturing as well for specific elements in the process.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Recent Videos
Pharm Tech Group looks at the challenges surrounding the development and manufacture of ATMPs in more detail with Agne Vaitkeviciene, CEO of Memel Biotech.
Pharm Tech Group sits down with Bernard Sagaert, CEO of etherna, to examine the role of mRNA in the treatment of autoimmune diseases.
Pharm Tech Group chats with Dr. Monika Paulė, CEO and co-founder of Caszyme about the evolution of CRISPR.
Related Content